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Purpose: The GOLD report provides a framework for classifying COPD in a way that reflects 
its clinical impact and allows treatment recommendations. The GOLD 2017 proposes a new 
classification whereby patients are grouped as A–D according to their symptoms and history 
of exacerbations. However, the clinical characteristics and outcomes in these patients are not 
well documented.
Patients and methods: In this prospective observational study, we analyzed data from the 
Ishinomaki COPD Network Registry. All patients with stable COPD were classified into the 
four groups defined by GOLD 2017. The patient demographics, clinical characteristics, number 
of exacerbations, and mortality rate during 1 year of follow-up were compared between the 
groups.
Results: Four hundred and one patients with stable COPD were identified. There were 240 
patients (59.9%) in group A, 122 (30.4%) in group B, 16 (4.0%) in group C, and 23 (5.7%) in 
group D. Patients in groups B, C, and D had ORs of 2.95, 3.92, and 5.45, respectively, for risk 
of exacerbation relative to group A. Groups C and D experienced exacerbations more frequently, 
including exacerbations leading to hospital admission, than groups A and B (both P,0.001) 
during the 1-year follow-up period. Patients with a high risk of exacerbation (groups C and D) 
had a lower body mass index, showed more symptoms, used more respiratory medications, and 
had more severe airflow limitation than patients at low risk of exacerbation (groups A and B). 
Mortality was not different between the high-risk and low-risk groups.
Conclusion: The results of our study provide evidence that the GOLD 2017 classification 
identifies patients with COPD at risk of exacerbations, including those requiring hospitalization, 
but has a poor ability to predict mortality.
Keywords: chronic obstructive pulmonary disease, GOLD, GOLD 2017, exacerbations, mortality
Introduction
COPD is a common, preventable, and treatable disease characterized by persistent 
respiratory symptoms and airflow limitation caused by airway and/or alveolar abnor-
malities that develop in response to significant exposure to noxious particles or gases.1 
Management of stable COPD had been guided by the severity of airflow limitation 
(Table 1).2 However, patients with COPD show considerable heterogeneity in terms 
of their clinical presentation, response to therapy, and outcomes.3–5 The 2011 revision 
of GOLD report proposed the ABCD classification for COPD patients based on their 
symptoms, severity of airflow limitation, and history of exacerbations (Table 1).6 
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This assessment system was linked to the initial manage-
ment of the disease, including use of bronchodilators and 
inhaled corticosteroids. However, this ABCD system has 
some important limitations in that it performs no better than 
staging by spirometry for prediction of mortality7 or decline 
in pulmonary function.8 Therefore, the ABCD classification 
was revised in the 2017 GOLD report, in which spirometry 
measurements were removed from the classification and 
grouping is based on symptoms and exacerbation history 
(Table 1).1
Several studies have reported the clinical charac-
teristics and outcomes of COPD using the GOLD 2017 
classification.9–13 However, there were differences in the 
distribution of the A, B, C, and D groups between these 
studies. Moreover, the ability of the GOLD 2017 classifica-
tion to predict clinical outcomes, including exacerbation and 
mortality, is not well documented.
In this prospective observational study, we aimed to 
investigate the distribution of clinical phenotypes of COPD 
in a cohort of Japanese patients according to the GOLD 2017 
classification. We also evaluated the ability of the GOLD 
2017 classification to predict the risk of exacerbation and 
mortality during 1 year of follow-up.
Patients and methods
Study design
In this study, we analyzed the data that were prospectively 
collected at consecutive scheduled patient visits or from 
patients who were newly registered in the Ishinomaki COPD 
Network (ICON) Registry14,15 between May 2015 and 
August 2017.
Briefly, ICON is a regional medical liaison system that 
aims to provide comprehensive care to patients with COPD 
and is a part of a multicenter interdisciplinary collaboration 
between health care providers, including specialists in respi-
ratory medicine, nurse specialists, therapists, pharmacists, 
and general practitioners, in Ishinomaki, Japan. Patients 
registered in ICON Registry receive the standard of care 
in general practice clinics according to the guidelines.16,17 
The patients also undergo scheduled examinations and 
receive education at the Japanese Red Cross Ishinomaki 
Hospital (a 452-bed tertiary community hospital) every 
6–12 months. Patients who experience exacerbations are 
first treated by their general practitioners and then referred 
to the Japanese Red Cross Ishinomaki Hospital if necessary. 
The patient education program includes training on early 
recognition of exacerbation and a written action plan for 
an exacerbation using a self-management diary. Patients 
are prescribed short-acting bronchodilators, but not oral 
corticosteroids or antibiotics, for self-administration during 
exacerbations.
This research is a part of an ongoing COPD cohort study 
registered with the UMIN Clinical Trials Registry (identifier: 
UMIN000017376). The study was conducted in accordance 
with the ethical principles of the Declaration of Helsinki and 
was approved by the Ethics Committee of the Japanese Red 
Cross Ishinomaki Hospital (approval number: 12-14-1). All 
patients provided written informed consent.
Table 1 Overview of GOLD classification
1 II III IV
gOlD 2007 FeV1 $80% predicted 50% # FeV1 ,80%  
predicted
30% # FeV1 ,50%  
predicted
FeV1 #30% predicted or FeV1  
#50% predicted plus chronic  
respiratory failure
 A B C D
gOlD 2011 mMrC 0–1 and CaT ,10
gOlD 1 or 2
Exacerbation history 0–1
mMrC $2 or CaT $10
gOlD 1 or 2
Exacerbation history 0–1
mMrC 0–1 and CaT ,10
gOlD 3 or 4
Exacerbation history $2
mMrC $2 or CaT $10
gOlD 3 or 4
Exacerbation history $2
gOlD 2013 mMrC 0–1 and CaT ,10
gOlD 1 or 2
Exacerbation history 0 or  
1 (not leading to hospital  
admission)
mMrC $2 or CaT $10
gOlD 1 or 2
Exacerbation history  
0 or 1 (not leading to  
hospital admission)
mMrC 0–1 and CaT ,10
gOlD 3 or 4
Exacerbation history $2  
or $1 (leading to hospital  
admission)
mMrC $2 or CaT $10
gOlD 3 or 4
Exacerbation history $2 or $1  
(leading to hospital admission)
gOlD 2017 mMrC 0–1 and CaT ,10
Exacerbation history 0 or  
1 (not leading to hospital  
admission)
mMrC $2 or CaT $10
Exacerbation history  
0 or 1 (not leading to  
hospital admission)
mMrC 0–1 and CaT ,10
Exacerbation history $2  
or $1 (leading to hospital  
admission)
mMrC $2 or CaT $10
Exacerbation history $2 or$1  
(leading to hospital admission)
Note: The severity of airflow limitation since GOLD 2011 is classified as follows: GOLD 1, FEV1 $80% predicted; GOLD 2, 50% # FeV1 ,80% predicted; GOLD 3, 30% # 
FeV1 ,50% predicted; and GOLD 4, FEV1 ,30% predicted.
Abbreviation: CAT, COPD Assessment Test.
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Patients
Patients with stable COPD and aged $40 years were 
included in the study. Persistent airflow limitation, defined 
as a post-bronchodilator FEV
1
/FVC ,0.7, was confirmed by 
spirometry. The exclusion criteria were chronic bronchitis 
or emphysema without airflow limitation, history of lung 
resection or tuberculosis, and exacerbation of COPD in the 
4 weeks preceding collection of the data.
Clinical and physiological measurements
The sociodemographic characteristics and smoking history 
of each patient were recorded at baseline. Body mass index 
(BMI) was calculated in kg/m2. Dyspnea was evaluated using 
the mMRC dyspnea scale.16,17 COPD-related health status was 
assessed using the COPD Assessment Test (CAT), which is an 
eight-item questionnaire with possible scores ranging from 0 
to 40 and higher scores indicating worse quality of life.18,19
Exacerbations were defined as the use of antibiotics and/or 
systemic corticosteroids for worsening respiratory symptoms 
with no evidence indicating an alternative diagnosis.1 Mild 
exacerbations treated with short-acting bronchodilators only 
were not considered in the study.
All pulmonary function tests were performed while the 
patients were in a stable condition and by a well-trained 
technician following the guidelines.20 The severity of airflow 
limitation was classified as follows: GOLD 1, FEV
1
$80% 
predicted; GOLD 2, 50% # FEV
1
,80% predicted; GOLD 3, 
30% # FEV
1
,50% predicted; and GOLD 4, FEV
1
#30% 
predicted.1 The ABCD grouping was performed in accordance 
with GOLD 2011, GOLD 2013, and GOLD 2017 (Table 1).
longitudinal assessment
The exacerbation rate during the 1-year follow-up was 
evaluated at scheduled annual visits by direct patient inter-
view, self-management diaries completed by the patient or 
caregiver, referral letters from general practitioners, and 
review of medical records. Life status was assessed during 
the follow-up period.
Statistical analyses
The data are shown as median (interquartile range) or 
mean ± SD unless otherwise specified. The baseline character-
istics of the subjects in the four GOLD groups were compared 
using one-way ANOVA or Kruskal–Wallis test. Differences 
between two groups were assessed using Student’s t-test 
or Mann–Whitney U test. Fisher’s exact test was used to 
determine the association between categorical variables. 
The ORs of exacerbations and mortality were estimated by 
logistic regression analysis. All statistical analyses were per-
formed using EZR (Saitama Medical Center, Jichi Medical 
University, Saitama, Japan), a graphical user interface 
for R (The R Foundation for Statistical Computing, Vienna, 
Austria).21 P-values ,0.05 were considered statistically 
significant.
Results
Distribution of ABCD groups in the study 
patients
Four hundred and one patients with stable COPD (362 men, 
39 women; median age 75 years) were identified. The distri-
bution of groups A, B, C, and D according to GOLD 2011, 
GOLD 2013, and GOLD 2017 is shown in Figure 1. Accord-
ing to the GOLD 2017 classification, 240 patients (59.9%) 
were in group A, 122 (30.4%) were in group B, 16 (4.0%) 
were in group C, and 23 (5.7%) were in group D. Fourteen 
(3.5%) of the 401 patients who were at low risk (groups A 
and B) according to the GOLD 2011 classification were 
reclassified as being at high risk (groups C and D) accord-
ing to the GOLD 2017 classification (from group A to C, 
n=11; from group B to D, n=3). Furthermore, 89 (22.2%) of 
those who were at high risk according to the GOLD 2011 
classification were reclassified as being at low risk according 
to the GOLD 2017 classification (from group C to A, n=34; 
from group D to B, n=55).
According to the GOLD 2017 classification, the majority 
of patients with mild airflow limitation were categorized 
as group A (Figure 2). In contrast, those with more severe 
airflow limitation were more evenly distributed across the 
four groups, although it should be noted that the number of 
patients was small.
Clinical phenotypes of the study 
patients according to the gOlD 2017 
classification
The clinical characteristics of each group according to the 
GOLD 2017 classification are shown in Table 2.
The more symptomatic patients (groups B and D) were 
older and had a lower BMI, lower FEV
1
, and more severe air-
flow limitation than the less symptomatic patients (groups A 
and C; Table 3). The more symptomatic groups tended to 
use more respiratory medications than the less symptomatic 
groups.
Patients at a high risk of exacerbation (groups C and D) 
had a lower BMI, lower FEV
1
, and more severe airflow limi-
tation than those at low risk of exacerbation (groups A and B; 
Table 4). The high-risk patients were also more symptomatic 
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(according to their mMRC dyspnea scale and CAT scores) 
and tended to use more respiratory medications than the low-
risk patients. There was no significant difference in mean 
patient age, proportion of men, or proportion of patients with 
a smoking history between the groups.
Outcomes according to aBCD 
classification
Three hundred and ninety-six (98.8%) of the 401 patients 
completed the 1-year follow-up. The frequency of 
exacerbations during this time was 0.16±0.46 events per 
person per year and that of severe exacerbations leading to 
hospital admission was 0.098±0.35 events per person per 
year. No exacerbations were observed in 346 (87.3%) of 
396 patients, and only 10 (2.5%) had frequent (two or more) 
exacerbations per year.
According to the GOLD 2017 classification, the fre-
quency of exacerbations was 6.4% (15/235) in group A, 
18.9% (23/122) in group B, 25.0% (4/16) in group C, and 
34.8% (8/23) in group D during the study period. Patients in 
$ % & '
   *2/'
   *2/'
   *2/'
Figure 1 Distribution of A, B, C, and D groups according to GOLD 2011, GOLD 2013, and GOLD 2017 in the study population. 
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Clinical characteristics and outcomes of COPD
groups B, C, and D had ORs of 2.95 (95% CI 1.60–5.45), 
3.92 (95% CI 1.47–10.4), and 5.45 (95% CI 2.59–11.5), 
respectively, for risk of exacerbations relative to group A 
(Table 5). The frequency of severe exacerbations requiring 
hospitalization was 1.7% (4/235) in group A, 13.9% (17/122) 
in group B, 12.5% (2/16) in group C, and 30.4% (7/23) in 
group D. Patients in groups B, C, and D had ORs of 8.19 
(95% CI 2.82–23.8), 7.34 (95% CI 1.45–37.1), and 17.9 
(95% CI 5.65–56.5), respectively, for risk of exacerbations 
requiring hospitalization relative to group A (Table 5). The 
patients at high risk of exacerbations (groups C and D) had 
significantly more frequent exacerbations, including severe 
exacerbations leading to hospital admission, than those at 
low risk (groups A and B; both P,0.001; Table 6).
According to the GOLD 2017 classification, all-cause 
mortality was 1.3% (3/235) in group A, 4.9% (6/122) in 
group B, 0% (0/16) in group C, and 4.3% (1/23) in group D 
during the study period. Patients in groups B and D had ORs 
of 3.85 (95% CI 0.98–15.1) and 3.41 (95% CI 0.37–31.4), 
respectively, for mortality relative to group A (Table 5). 
Mortality was not significantly different between the high-
risk and low-risk groups (Table 6). According to the GOLD 
2011 classification, all-cause mortality was 1.4% (3/212) 
in group A, 5.7% (4/70) in group B, 0% (0/39) in group C, 
and 4.0% (3/75) in group D. According to the GOLD 2013 
classification, all-cause mortality was 1.5% (3/201) in 
group A, 6.0% (4/67) in group B, 0% (0/39) in group C, 
and 3.8% (3/78) in group D. Mortality was not significantly 
*2/'Q   
*2/'Q   

*2/'Q    
*2/'Q     
$ % & '
Figure 2 Distribution of GOLD stages of airflow limitation in the study population.
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Table 2 Characteristics of the study patients at baseline according to the ABCD classification (n=401)
 A (n=240) B (n=122) C (n=16) D (n=23) P-value
Age (years) 73.3±6.8 77.8±7.6 74.6±8.9 74.8±8.1 ,0.001
Male sex 216 (90.0) 110 (90.2) 15 (93.8) 21 (91.3) 0.966
BMI 23.8±3.7 23.4±4.3 24.0±3.7 20.8±3.4 0.0024
Smoking history (pack-years) 54.8±29.0 54.4±34.9 51.7±28.1 57.1±29.4 0.953
FeV1 (l) 1.76±0.56 1.26±0.56 1.59±0.53 0.83±0.36 ,0.001
%FeV1 (%) 68.5±17.9 55.6±23.0 61.6±13.8 35.4±15.8 ,0.001
FVC (l) 3.28±0.78 2.80±2.20 3.20±0.91 2.46±0.55 ,0.001
gOlD stage     ,0.001
1 67 (27.9) 18 (14.7) 0 (0) 0 (0)  
2 139 (57.9) 49 (40.2) 15 (93.8) 3 (13.0)  
3 31 (12.9) 40 (32.8) 0 (0) 8 (34.8)  
4 3 (1.3) 15 (12.3) 1 (6.2) 12 (52.2)  
mMRC dyspnea scale score 0.5±0.5 2.0±0.9 0.5±0.5 2.4±0.8 ,0.001
CaT score 3.7±2.6 11.5±6.5 3.3±2.4 11.7±6.9 ,0.001
regular medicationa     ,0.001
laMa 85 (35.4) 31 (25.4) 7 (43.8) 0  
laBa 20 (8.3) 6 (2.7) 0 0  
ICs 1 (0.4) 1 (0.8) 0 0  
laMa/laBa 44 (18.3) 23 (18.9) 4 (25.0) 9 (39.1)  
ICs/laBa 14 (5.8) 4 (3.3) 0 0  
ICs/laMa 5 (2.1) 1 (0.8) 0 0  
laMa/laBa/ICs 57 (23.8) 54 (44.3) 5 (31.3) 14 (60.9)  
none 14 (5.8) 2 (1.6) 0 0  
Home oxygen therapy 4 (1.7) 28 (23.0) 0 12 (52.2) ,0.001
Exacerbation historyb 0.067 0.082 1.31 1.13 ,0.001
Notes: The data are shown as mean ± sD or as number (percentage). anumbers of long-acting bronchodilators or inhaled corticosteroids. bFrequency of exacerbations 
during the previous year at baseline (events per person per year).
Abbreviations: BMI, body mass index; CAT, COPD Assessment Test; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic 
antagonist.
Table 3 Comparison of the clinical phenotype of less symptomatic patients (groups A and C) with that of more symptomatic patients 
(groups B and D)
 Less symptomatic group 
(n=256)
More symptomatic group 
(n=145)
P-value
Age (years) 73.3±6.9 77.3±7.7 ,0.001
Male sex 231 (90.2) 131 (90.3) 0.972
BMI 23.8±3.7 23.0±4.2 0.0297
Smoking history (pack-years) 54.6±28.9 54.9±34.0 0.932
FeV1 (l) 1.75±0.56 1.19±0.56 ,0.001
%FeV1 (%) 68.1±17.7 52.4±23.2 ,0.001
FVC (l) 3.28±0.78 2.75±2.03 ,0.001
mMRC dyspnea scale score 0.5±0.5 2.0±0.9 ,0.001
CaT score 3.7±2.6 11.5±6.5 ,0.001
regular medicationa   ,0.001
1 113 (44.1) 38 (26.2)  
2 67 (26.2) 37 (25.3)  
3 62 (24.2) 68 (46.9)  
Home oxygen therapy 4 (1.6) 40 (27.6) ,0.001
Exacerbation historyb 0.14±0.17 0.25±0.23 0.0233
Notes: The data are shown as mean ± sD or as number (percentage). anumbers of long-acting bronchodilators and inhaled corticosteroids. bFrequency of exacerbations 
during the previous year at baseline (events per person per year).
Abbreviations: BMI, body mass index; CAT, COPD Assessment Test.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
6.
77
.5
6.
92
 o
n 
21
-A
pr
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3953
Clinical characteristics and outcomes of COPD
different between the A, B, C, and D groups according to 
the GOLD 2011 or GOLD 2013 classification (P=0.13 and 
P=0.11, respectively).
Discussion
We have shown the distribution of clinical phenotypes of 
COPD according to the GOLD 2017 ABCD classification in 
a cohort of Japanese patients with COPD. The distribution 
of patients across the four groups in our study was different 
from that in previous studies.9–13 There may be differences 
in the COPD phenotypes, including frequency of exacerba-
tions, comorbidities, and causes of death, depending on race, 
region, and the health care system.
The participants in this study included a small proportion 
(approximately 10%) of patients in groups C and D, which 
reflects the relatively low frequency of exacerbations in the 
study population. In the Hokkaido COPD cohort study,22 
which included a different Japanese COPD cohort, Suzuki 
et al demonstrated that the frequency of exacerbation was 
0.20 events per person per year when defined by a prescrip-
tion change and 0.13 events per year per person when defined 
by the use of antibiotics. Furthermore, the frequency of 
hospitalization for an exacerbation of COPD was 0.06 events 
per person per year. Our present findings are consistent with 
those of the Hokkaido COPD cohort study.
In this study, there were differences in clinical phenotypes 
between patients in groups A–D. The patients tended to 
receive more intensive treatment than that recommended in 
the GOLD 2017 report, possibly because the treatment options 
were selected in accordance with the earlier guidelines6,16 and 
because step-down therapy is rarely undertaken in patients 
whose symptoms have improved on intensive treatment.
The results of our study show that the GOLD 2017 
classification identifies patients at risk of exacerbation. 
Exacerbations of COPD are associated with decreased lung 
function,23 poorer health status,24 and increased mortality 
risk.23,25 Therefore, assessment of stable COPD should 
include evaluation of the risk of exacerbation. Recently, 
Hurst et al reported that the history of exacerbations was 
the best predictor of frequent exacerbations (two or more 
per year).26 The GOLD 2017 classification proposes that 
an exacerbation history (two or more exacerbations or one 
or more exacerbation leading to hospital admission in the 
previous year) is associated with an increased risk of further 
Table 4 Comparison of the clinical phenotype of patients at low risk (groups A and B) with that of patients at high risk (groups C and D)
 Low-risk group (n=356) High-risk group (n=39) P-value
Age (years) 74.8±7.4 74.7±8.3 0.942
Male sex 326 (91.6) 36 (92.3) 0.653
BMI 23.7±3.8 22.1±3.8 0.0168
Smoking history (pack-years) 54.7±31.0 54.8±28.7 0.973
FeV1 (l) 1.59±0.61 1.14±0.57 ,0.001
%FeV1 (%) 64.2±20.7 46.1±19.8 ,0.001
FVC (l) 3.28±0.78 2.75±2.03 ,0.001
mMRC dyspnea scale score 1.0±1.0 1.6±1.2 ,0.001
CaT score 6.3±5.7 8.3±6.9 0.0496
regular medicationa   0.0049
1 144 (40.4) 7 (17.9)  
2 91 (25.6) 13 (33.3)  
3 111 (31.2) 19 (48.7)  
Home oxygen therapy 32 (9.0) 12 (30.8) ,0.001
Exacerbation historyb 0.072±0.259 1.20±0.47 ,0.001
Notes: The data are shown as mean ± sD or as number (percentage). anumbers of long-acting bronchodilators and inhaled corticosteroids. bFrequency of exacerbations 
during the previous year at baseline (events per person per year).
Abbreviations: BMI, body mass index; CAT, COPD Assessment Test.
Table 5 ORs of all exacerbations, exacerbations leading to hospital admission, and all-cause mortality according to the ABCD classification
 A B C D
exacerbations 1 2.95 (1.60–5.45) 3.92 (1.47–10.4) 5.45 (2.59–11.5)
exacerbations leading to hospital admission 1 8.19 (2.82–23.8) 7.34 (1.45–37.1) 17.9 (5.65–56.5)
All-cause mortality 1 3.85 (0.98–15.1) 0 3.41 (0.37–31.4)
Note: The data are shown as Or (95% CI).
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exacerbations. We found that groups C and D experienced 
more exacerbations, especially those requiring hospital-
ization, than groups A and B. These results indicate that 
the GOLD 2017 classification identifies patients at risk of 
moderate-to-severe exacerbations, including those requiring 
hospitalization, even in the COPD population with a low 
frequency of exacerbations.
The findings of our study suggest that patients with 
a lower BMI, more symptoms, and more severe airflow 
limitation may be at risk of exacerbations. These results are 
congruent with those of previous studies demonstrating an 
association between deteriorating airflow limitation and an 
increasing prevalence of exacerbations23 and hospitalization.27 
Low BMI28 and the presence of more symptoms29 have been 
identified as possible risk factors for exacerbations. Patients 
with such a phenotype might be at risk of exacerbations.
The results of our study support the view that the 
GOLD 2017 classification has a poor ability to predict 
mortality and are consistent with the findings of other recent 
studies.11,13 Cabrera López et al recently demonstrated that 
the risk of mortality in groups B and D was higher than that 
in groups A and C.11 In our study, the 1-year mortality in 
groups B and D tended to be higher than that in groups A 
and C, which suggests that symptoms are more important than 
the exacerbation history when evaluating the mortality risk. 
Novel prognostic factors might be considered for evaluating 
mortality aside from the ABCD classification.
The primary strengths of our study are its prospective 
observational design and inclusion of community-dwelling 
patients treated by general practitioners in Ishinomaki or the 
surrounding cities, meaning that our study population reflects 
the real-world COPD population in Japan. However, the 
study also has some potential limitations. First, the follow-up 
duration was only 1 year. Second, the sample size was smaller 
than that in the previous large-scale studies.9–13 A longer-term 
follow-up study with a larger group of patients is needed.
Conclusion
We have shown the distribution of clinical phenotypes of 
COPD according to the GOLD 2017 ABCD classification 
in a cohort of Japanese patients with COPD. The results of 
our study demonstrate that the GOLD 2017 classification 
system identifies patients at risk of exacerbation but has a 
poor ability to predict mortality.
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